Cardiff Oncology (CRDF) Stock Price, News & Analysis

Company Overview

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing cancer therapies designed to target difficult-to-treat tumors. The company’s lead investigational product is onvansertib, an oral, highly selective inhibitor of polo-like kinase 1 (PLK1), a protein involved in cell division and tumor growth.

Cardiff Oncology has primarily evaluated onvansertib in combination with existing treatments for patients with RAS-mutated metastatic colorectal cancer, including regimens involving chemotherapy and targeted agents. The company has also investigated the drug in other oncology settings, including prostate cancer. Onvansertib is an investigational therapy and is not an approved commercial product.

The company was formerly known as Trovagene, Inc. and adopted the Cardiff Oncology name in 2020 to reflect its focus on cancer drug development. Cardiff Oncology is headquartered in San Diego, California, and advances its programs through clinical research conducted with medical institutions and development partners. Mark Erlander has served as the company’s chief executive officer.

Key Stats

• Today's Range: $0.96 to $1.06
• 50-Day Range: $0.88 to $1.37
• 52-Week Range: $0.76 to $3.31
• Volume: 412,914 shs
• Average Volume: 585,745 shs
• Market Capitalization: $75.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Hold

Cardiff Oncology Stock Analysis - MarketRank™

Cardiff Oncology scored higher than 49% of companies evaluated by MarketBeat, and ranked 571st out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Hold

Consensus Rating

Cardiff Oncology has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Cardiff Oncology has a consensus price target of $7.50, representing about 670.5% upside from its current price of $0.97.

Amount of Analyst Coverage

Cardiff Oncology has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cardiff Oncology are expected to grow in the coming year, from ($0.60) to ($0.56) per share.

Price to Book Value per Share Ratio

Cardiff Oncology has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.02% of the float of Cardiff Oncology has been sold short.

Short Interest Ratio / Days to Cover

Cardiff Oncology has a short interest ratio ("days to cover") of 17.19, which indicates bearish sentiment.

Change versus previous month

Short interest in Cardiff Oncology has recently decreased by 1.90%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cardiff Oncology does not currently pay a dividend.

Dividend Growth

Cardiff Oncology does not have a long track record of dividend growth.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.42

News Sentiment

Cardiff Oncology has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cardiff Oncology this week, compared to 3 articles on an average week.

Search Interest

5 people have searched for CRDF on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

MarketBeat Follows

6 people have added Cardiff Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cardiff Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.80% of the stock of Cardiff Oncology is held by insiders.

Percentage Held by Institutions

16.29% of the stock of Cardiff Oncology is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CRDF
• CIK: 1213037
• Web: cardiffoncology.com
• Phone: (858) 952-7570
• Fax: N/A
• Employees: 31
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Cardiff Oncology: $7.50
• High Price Target: $12.00
• Low Price Target: $2.00
• Potential Upside/Downside: +670.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.29
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.85 million
• Net Margins: -7,885.43%
• Pretax Margin: -7,884.06%
• Return on Equity: -103.10%
• Return on Assets: -75.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.30
• Quick Ratio: 3.30

Sales & Book Value

• Annual Sales: $508 thousand
• Price / Sales: 149.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.67 per share
• Price / Book: 1.45

Miscellaneous

• Outstanding Shares: 77,795,000
• Free Float: 70,949,000
• Market Cap: $75.73 million
• Optionable: Optionable
• Beta: 1.42